A randomized, controlled, open-label, multicenter, phase II study of the safety and efficacy of sunitinib in combination with bevacizumab, carboplatin, and paclitaxel in previously untreated patients with advanced non-small cell lung cancer.

Trial Profile

A randomized, controlled, open-label, multicenter, phase II study of the safety and efficacy of sunitinib in combination with bevacizumab, carboplatin, and paclitaxel in previously untreated patients with advanced non-small cell lung cancer.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 25 Nov 2014

At a glance

  • Drugs Bevacizumab (Primary) ; Sunitinib (Primary) ; Carboplatin; Paclitaxel
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms SABRE-L
  • Sponsors Genentech
  • Most Recent Events

    • 22 Dec 2009 Results published in the Journal of Thoracic Oncology.
    • 25 Aug 2009 Planned end date (Apr 2008) added as reported by ClinicalTrials.gov.
    • 25 Aug 2009 Additional lead trial investigator Hambleton J identified, actual patient number (56) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top